PHARMANIAGA BHD

KLSE (MYR): PHARMA (7081)

You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!

Last Price

0.355

Today's Change

-0.005 (1.39%)

Day's Change

0.355 - 0.36

Trading Volume

442,000

Financial
Market Cap

Market Cap

512 Million

NOSH

1,441 Million

Latest Quarter

Latest Quarter

30-Jun-2024 [#2]

Announcement Date

21-Aug-2024

Next Quarter

30-Sep-2024

Est. Ann. Date

29-Nov-2024

Est. Ann. Due Date

29-Nov-2024

QoQ | YoY

-89.09% | 42.63%

T4Q Result

Revenue | NP to SH

3,478,508.000 | -53,617.000

RPS | P/RPS

241.36 Cent | 0.15

EPS | P/E | EY

-3.72 Cent | -9.54 | -10.48%

DPS | DY | Payout %

0.00 Cent | 0.00% | 0.00%

NAPS | P/NAPS

-0.19 | 0.00

QoQ | YoY

1.54% | 91.51%

NP Margin | ROE

-1.47% | 0.00%

F.Y. | Ann. Date

30-Jun-2024 | 21-Aug-2024

Latest Audited Result

Latest Audited Result

31-Dec-2023

Announcement Date

29-Apr-2024

Next Audited Result

31-Dec-2024

Est. Ann. Date

29-Apr-2025

Est. Ann. Due Date

29-Jun-2025

Annual (Unaudited)

Revenue | NP to SH

3,404,481.000 | -77,452.000

RPS | P/RPS

236.22 Cent | 0.15

EPS | P/E | EY

-5.37 Cent | -6.61 | -15.14%

DPS | DY | Payout %

0.00 Cent | 0.00% | 0.00%

NAPS | P/NAPS

-0.20 | 0.00

YoY

87.25%

NP Margin | ROE

-2.23% | 0.00%

F.Y. | Ann. Date

31-Dec-2023 | 29-Feb-2024

Annualized Result

Revenue | NP to SH

3,606,430.000 | 56,886.000

RPS | P/RPS

250.23 Cent | 0.14

EPS | P/E | EY

3.94 Cent | 8.99 | 11.12%

DPS | DY | Payout %

-

NAPS | P/NAPS

-

QoQ | YoY

-44.55% | 517.25%

NP Margin | ROE

1.67% | 0.00%

F.Y. | Ann. Date

30-Jun-2024 | 21-Aug-2024

Business Process

Trailing 4 Quarters Trailing 8 Quarters
Available Quarters 4 Quarters 8 Quarters
Continuous Quarters Of Revenue Growth 0 / 4 0.00% 0 / 8 0.00%
Total Positive Profit Years 2 / 4 50.00% 5 / 8 62.50%
Continuous Quarters Of Positive Profit 2 / 4 50.00% 2 / 8 25.00%
Continuous Quarters Of Profit Growth 0 / 4 0.00% 0 / 8 0.00%
Continuous Quarters Of Adjusted EPS Growth 0 / 4 0.00% 0 / 8 0.00%
Total Dividend Years 0 / 4 0.00% 1 / 8 13.00%
Continuous Quarters Of Dividend 0 / 4 0.00% 0 / 8 0.00%
Continuous Quarters Of Dividend Growth 0 / 4 0.00% 0 / 8 0.00%
Continuous Quarters Of Adjusted Dps Growth 0 / 4 0.00% 0 / 8 0.00%
Average ROE 0.00% 0.26%
Average Net Profit Margin -1.61% -9.94%

Last 5 Financial Years Last 10 Financial Years
Available Years 5 Years 10 Years
Continuous Quarters Of Revenue Growth 0 / 5 0.00% 0 / 10 0.00%
Total Positive Profit Years 2 / 5 40.00% 7 / 10 70.00%
Continuous Quarters Of Positive Profit 0 / 5 0.00% 0 / 10 0.00%
Continuous Quarters Of Profit Growth 1 / 5 20.00% 1 / 10 10.00%
Continuous Quarters Of Adjusted EPS Growth 1 / 5 20.00% 1 / 10 10.00%
Total Dividend Years 4 / 5 80.00% 9 / 10 90.00%
Continuous Quarters Of Dividend 0 / 5 0.00% 0 / 10 0.00%
Continuous Quarters Of Dividend Growth 0 / 5 0.00% 0 / 10 0.00%
Continuous Quarters Of Adjusted Dps Growth 0 / 5 0.00% 0 / 10 0.00%
Average ROE 0.41% 6.29%
Average Net Profit Margin -4.04% -0.57%
Key Result

T4Q Annualized Annual (Unaudited) Last 10 FY Average Last 5 FY Average
Revenue 3,478,508 3,606,430 3,404,481 2,848,595 3,455,154
NP to SH -53,617 56,886 -77,452 -31,457 -126,869
Dividend 0 0 0 48,015 39,519
Adjusted EPS -3.72 3.94 -5.37 -2.18 -8.80
Adjusted DPS 0.00 0.00 0.00 3.33 2.74

NP to SH = Net Profit Attributable to Shareholder, EPS = Earning Per Share, DPS = Dividend Per Share

All figures in '000 unless specified.

EPS & DPS's figures in Cent.

Growth

LQ QoQ LQ YoY CQ YoY LQ vs Average of T4Q LQ vs Average of T8Q
Revenue -13.13% -1.23% 4.28% -3.61% -4.13%
NP to Owner -89.09% 42.63% 517.25% 120.87% 103.27%
Dividend 0.00% 0.00% 0.00% 0.00% 0.00%
Adjusted EPS -89.33% 39.64% 516.15% 120.41% 103.20%
Adjusted DPS 0.00% 0.00% 0.00% 0.00% 0.00%

LQ = Latest Quarter, CQ = Cumulative Quarter, T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, QoQ = Quarter on Quarter, YoY = Year on Year

T4Q vs LFY T4Q vs AL5FY T4Q vs AL10FY AQR vs LFY AQR vs AL5FY AQR vs AL10FY LFY YoY LFY vs AL5FY LFY vs AL10FY
Revenue 2.17% 0.68% 22.11% 5.93% 4.38% 26.60% -3.02% -1.47% 19.51%
NP to Owner 30.77% 57.74% -70.44% 173.45% 144.84% 280.84% 87.25% 38.95% -146.21%
Dividend 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Adjusted EPS 30.78% 57.74% -70.43% 173.32% 144.76% 280.51% 87.25% 38.95% -146.21%
Adjusted DPS 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, AL5FY = Average of Last 5 Financial Years, AL10FY = Average of Last 10 Financial Years, LFY = Latest Financial Year AQR = Annualized Quarter Result, YoY = Year on Year

Discussions
6 people like this. Showing 50 of 14,129 comments

Ron90

this is not a problematic company, its the gahmen yg forced them to hsndle covid vaccine till over supply..when kovid gone..stuck with oversupply dose.. ask Kj ler. now, gahmen hv silently help to fix the problem. Nx Qr will be more prolific..high probability Revenue over 1b. Current price consider low already..good to enter. Down side minimum..upper side. 50 cents 👍

2024-07-05 19:05

Ron90

might get release from PN17 status, anytime soon :-)

2024-07-09 09:25

RInvest

Looking good ...

2024-07-09 11:29

newbie9893

Phama resistance breakout...heading to 0.5

2024-07-09 11:31

AlanTew

Look at other pharma players, their shares are all above RM2. This is the reason I said Pharmaniaga is underrated and it should be priced about RM4 if they are managing it well like others.

2024-07-09 12:29

Ron90

current management good already, managed to submit their restructuring plan early this year, you compare with other PN17 company, take yearssss to submit even the first plan. % months olready, and Bursa should give the approval anytime soon. I would expect this month.. BTW, Next QR should touch 1 billion revenue. Imagine how many people in Indonesia?? They just open news branch in Feb 2024.. next QR will be full 3 months (mac - June) sales.

" In the Indonesia segment, the revenue growth was due to the surge in demand for products of existing principals and additional sales generated from the opening of two
new branches in February 2024."

2024-07-09 13:53

newbie9893

pharma..uptread mode..buy now to be rewarded soon

2024-07-10 16:15

AlanTew

it will keep moving up steadily until the next QR released, if the report is good it will goes up further above RM1, and how high it could goes higher depends on the consistency of their financial performance as well as dividend given.

2024-07-10 17:36

AlanTew

Good morning guys, would like to congrats those who bought pharma at 30+- cents, the huge profit is awaiting us.

2024-07-11 09:17

AlanTew

for those who still have bullets may consider to get a train ticket asap as the gap of the stock price as of now to it supposed to be is big. big potential stock for mid term good profit investment.

2024-07-11 09:22

AmirIffaan

Ada LTAT, kutip sahaja semasa Pharma adalah murah

2024-07-11 20:21

Ron90

either regulation plan approved by Bursa or 1 billion revenue will makes this counter fly towards at least 50 cents! .

2024-07-11 20:54

Ron90

didnt seem to stop... up up .. :-)

2024-07-15 14:42

AlanTew

It will be keep going up for sure as the company is in good shape now and keep improving from varies aspects. Bear in mind pharma is essential and is must + Pharmaniaga is the sole appointed supplier of nation.

2024-07-15 17:59

Ron90

anticipating Bursa announcement about its regulation plan. Once out, should prepare how to act ..

2024-07-16 01:05

Jojo3826

Harap lepas 45sen today

2024-07-17 12:12

AmirIffaan

Sudah habis cuci la, notinside751 dan Pharma sedang naik sekarangan

2024-07-17 12:27

Ron90

patient.. next QR will produce revenue above 1 Billion.. and out from PN17 status!. Grab it while still below 50 cents.. end of year above 60 cents

2024-07-18 12:28

notinside751

Regularisation approved?

2024-07-18 13:48

soon9913

And the catalyst that is likely to change the fortunes of the company — a proposed renounceable rights issue with warrants as a sweetener to shareholders that is slated to raise up to RM354.6 million; and, more importantly, a proposed private placement to a third-party investor or investors that could raise gross proceeds of up to RM300 million — could happen soon. Both the rights issue and placement are part of a regularisation plan to get Pharmaniaga out of PN17 classification, but are likely to have a far-reaching impact if management’s plans pan out.

2024-07-21 15:12

soon9913

Don't all in, get ready some money to subscribe the right issue

2024-07-21 15:12

Ron90

got nothing to do with Biden drops from presidential race .. people over here still need pills and treatment. Pelaung to top up😅

2024-07-22 11:42

notinside751

Regularisation approved but tak boleh naik.

2024-07-24 11:07

soon9913

bukan x boleh naik, is ppl sell on news!

2024-07-24 16:19

Jojo3826

Itu mungkin indication harga right issue untuk 5 hari trading day

2024-07-24 16:56

notrealBoo

why keep press down? why don't want to let it up?

2024-07-25 18:13

Michael Kwok

Pharma 41.5
Tp 35 cents below.
26/7/24 1.30pm

2024-07-26 13:26

AmirIffaan

Tunggu keputusan q2 keluar dan tengok ...Jika bagus, ia akan naik

2024-07-27 10:01

DrLimKH

C wave otw to find new low. B wave had abc where Ba=Bc

2024-07-31 22:56

RInvest

Is there a dateline set by BURSA for PN17 status to be removed? Anyone knows?

2024-08-01 08:16

AmirIffaan

Michael Kwok dari Kenanga ? 🤔
https://klse.i3investor.com/web/pricetarget/research/72061

2024-08-02 18:29

Ron90

rare opportunity to grab at this level.. medical sector will not be affected by US burst.

2024-08-05 15:05

Ron90

People still need treatments.. government continue with medical spending!. current price consider reasonable.. between 36 - 38 cents. In my opinion, medical sector will become safe heaven during this turmoil event

2024-08-05 15:15

AmirIffaan

nampaknya Pharma tak jatuh macam Michael dan Kenanga jangka 😄

2024-08-08 16:23

AmirIffaan

Pharma akan terbang jika keputusan q2 cantik 🙂

2024-08-20 20:48

soon9913

OTHERS | https://www.klsescreener.com/v2/announcements/view/7963613

Omg resignation of auditors

2 months ago

XinXin Chan

Auditor resign.....gg.com

2 months ago

modestos

will not drop drastic. looking forward for upliftment next month

2 months ago

fruitcake

0.085 incoming😂

2 months ago

GlobalEquity


*** All look well.
*** Timely announcement: E&Y.
*** Improving biz trends.
*** Should be hot upon PN17 exit!

1 month ago

Newplayer01

I think market are just waiting for uplift of PN17. Look at Dpharma, already up so much. Soon will be us.

1 month ago

Ron90

price very stable at this pn17 lever.. think the opportunity once it cleared?

1 month ago

Bull13

Tuesday October 1st ..PN 17 Uplifting announcement??

1 month ago

RInvest

movement looks like expecting upliftment

1 month ago

Ron90

bursa so lazy, its been mora than 6 month, not reply ..PMx should bur$4 activities which always favour the speculators!! so lazy la..

1 month ago

Mkttalk

Good business but need better and experienced directors to provide oversight .

3 weeks ago

Ron90

this company falls under strategic and security for the nation, asclong as no corrupt or mismanagmnt.. gahmen will always give support. Previous disaster due to previous govt request to stockile vaccine ..in the end, they dont buy. Ltat n bousted..may be replaced by khazanah or pnb, kwsp.

3 days ago

Ron90

waiting for major announcement ..

2 days ago

rhtc88

Bad QR incoming?

1 day ago

Post a Comment